AC220 (Quizartinib) is a orally-administered, potent and selective inhibitor of two receptor tyrosine kinases, FLT3 and KIT. AC220 is currently in a Phase 2 clinical study in the relapsed/refractory AML patient population with internal tandem duplication (ITD positive) activating mutations of the FLT3 kinase (FLT3-ITD positive). AC220 (Quizartinib) exhibits low nanomolar potency in biochemical and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily. While other agents showed some ability to clear leukemia from the circulating blood, AC220 has shown significant ability to clear leukemic cells from the bone marrow, where the disease originates. AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.
Drug Des Devel Ther. 2018 Apr 30;12:1009-1017.
Advances in the drug therapies of acute myeloid leukemia (except acute promyelocytic leukemia)
AC220 purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | MV4-11 and RS4;11 cells |
Preparation method | Cellular assays. MV4-11 and RS4;11 cells were cultured in Iscove media with 10% fetal bovine serum (FBS) and RPMI complete with 10% FBS, respectively. For proliferation assays, cells were cultured overnight in low serum media (0.5% FBS), then seeded in a 96-well plate at 40 000 cells per well. Inhibitors were added to the cells and incubated at 37°C for 72 hours. Cell viability was measured using the Cell Titer-Blue Cell Viability Assay from Promega. To measure inhibition of FLT3 autophosphorylation, cells were cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells were incubated with inhibitors for 2 hours at 37°C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand (R&D Systems) was added for 15 minutes after the 2-hour compound incubation. Cell lysates were prepared and incubated in 96-well plates precoated with a total FLT3 capture antibody (R&D Systems). The coated plates were incubated with either a biotinylated antibody against FLT3 (R&D Systems) to detect total FLT3 or an antibody against phosphotyrosines (Millipore) to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody was used for electrochemiluminescence detection on the Meso Scale Discovery platform. |
Concentrations | 0~10 µM |
Incubation time | 72 h |
Animal Experiment | |
---|---|
Animal models | subcutaneous tumor model |
Formulation | 22% hydroxypropyl-β-cyclodextrin |
Dosages | 10 mg/kg |
Administration | orally |
Molecular Weight | 560.67 |
Formula | C29H32N6O4S |
CAS Number | 950769-58-1 |
Solubility (25°C) | DMSO ≥100 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related FLT3 Products |
---|
FLT3-IN-19
FLT3-IN-19 is a potent and selective FLT3 inhibitor with IC50 of 0.213 nM. |
LT-540-717
LT-540-717 is a potent FLT3 inhibitor (IC50=0.62 nM) with antiproliferative activity. |
GTP-14564
GTP-14564 is a tyrosine kinase inhibitor targeting to internal tandem duplication (ITD) and FLT3. |
HDAC-IN-63
HDAC-IN-63 is a dual FLT3/HDAC inhibitor (IC50: 0.844 and 30.0 nM for FLT3 and HDAC1 respectively). |
FLT3-IN-20
FLT3-IN-20 is a potent FLT3 inhibitor with IC50 values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.